E. coli remains one of the commercial turkey industry’s most costly disease concerns. As E. coli strains gradually increase in virulence and resistance, the use of common antibiotics is declining at many complexes.
An alternative to antibiotic treatment, Poulvac® E. coli allows veterinarians and live-production managers to help maximize flock performance, improve livability and reduce processing losses.
Up to the challenge
Performance improvements in two-dose program.1
A floor-pen challenge study examined the effect of Poulvac E. coli vaccination on key performance parameters.
At day of age, 144 turkey poults were given antibiotics in the hatchery, vaccinated for Newcastle disease and Hemorrhagic enteritis via drinking water and, 42 days later, infected with the O78 E. coli isolate. Poulvac E. coli was administered at 3 days of age and 21 days of age. The E. coli challenge was very severe, with over 50% mortality and 90% severe airsacculitis in the control group. At 49 days of age (seven days post-challenge), birds were evaluated to determine the cause of mortality and to measure severity of airsacculitis on a 0-to-3 scale.
Despite the strong challenge, Poulvac E. coli decreased mortality and severe airsacculitis with the two-dose administrations.*
Turkey-focused technical expertise
With the support of a team of representatives and veterinarians, Poulvac E. coli is helping every operation maximize its investment by building vaccination programs on farms and training teams on proper protocols.
In addition, production managers and veterinarians can manage other leading threats to turkey production with the full portfolio of Poulvac vaccines.
1 Data on file, Study Report No. FD-08-2, Zoetis LLC.